238 related articles for article (PubMed ID: 9813019)
1. Characterization of a heparin binding site on the heavy chain of factor XI.
Zhao M; Abdel-Razek T; Sun MF; Gailani D
J Biol Chem; 1998 Nov; 273(47):31153-9. PubMed ID: 9813019
[TBL] [Abstract][Full Text] [Related]
2. A binding site for heparin in the apple 3 domain of factor XI.
Ho DH; Badellino K; Baglia FA; Walsh PN
J Biol Chem; 1998 Jun; 273(26):16382-90. PubMed ID: 9632702
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
Yang L; Sun MF; Gailani D; Rezaie AR
Biochemistry; 2009 Feb; 48(7):1517-24. PubMed ID: 19178150
[TBL] [Abstract][Full Text] [Related]
4. Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa.
Wu W; Sinha D; Shikov S; Yip CK; Walz T; Billings PC; Lear JD; Walsh PN
J Biol Chem; 2008 Jul; 283(27):18655-64. PubMed ID: 18441012
[TBL] [Abstract][Full Text] [Related]
5. Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation.
Zivelin A; Ogawa T; Bulvik S; Landau M; Toomey JR; Lane J; Seligsohn U; Gailani D
J Thromb Haemost; 2004 Oct; 2(10):1782-9. PubMed ID: 15456490
[TBL] [Abstract][Full Text] [Related]
6. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity.
Rezaie AR; Sun MF; Gailani D
Biochemistry; 2006 Aug; 45(31):9427-33. PubMed ID: 16878977
[TBL] [Abstract][Full Text] [Related]
7. Factor XI anion-binding sites are required for productive interactions with polyphosphate.
Geng Y; Verhamme IM; Smith SA; Cheng Q; Sun M; Sheehan JP; Morrissey JH; Gailani D
J Thromb Haemost; 2013 Nov; 11(11):2020-8. PubMed ID: 24118982
[TBL] [Abstract][Full Text] [Related]
8. Structural role of Gly(193) in serine proteases: investigations of a G555E (GLY193 in chymotrypsin) mutant of blood coagulation factor XI.
Schmidt AE; Ogawa T; Gailani D; Bajaj SP
J Biol Chem; 2004 Jul; 279(28):29485-92. PubMed ID: 15090552
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa.
Geng Y; Verhamme IM; Sun MF; Bajaj SP; Emsley J; Gailani D
J Thromb Haemost; 2013 Jul; 11(7):1374-84. PubMed ID: 23617568
[TBL] [Abstract][Full Text] [Related]
10. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia.
Minnema MC; Pajkrt D; Wuillemin WA; Roem D; Bleeker WK; Levi M; van Deventer SJ; Hack CE; ten Cate H
Blood; 1998 Nov; 92(9):3294-301. PubMed ID: 9787166
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen-deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa.
Bar Barroeta A; van Galen J; Stroo I; Marquart JA; Meijer AB; Meijers JCM
J Thromb Haemost; 2019 Dec; 17(12):2047-2055. PubMed ID: 31519061
[TBL] [Abstract][Full Text] [Related]
12. The dimeric structure of factor XI and zymogen activation.
Geng Y; Verhamme IM; Smith SB; Sun MF; Matafonov A; Cheng Q; Smith SA; Morrissey JH; Gailani D
Blood; 2013 May; 121(19):3962-9. PubMed ID: 23515926
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor.
Wuillemin WA; Minnema M; Meijers JC; Roem D; Eerenberg AJ; Nuijens JH; ten Cate H; Hack CE
Blood; 1995 Mar; 85(6):1517-26. PubMed ID: 7534133
[TBL] [Abstract][Full Text] [Related]
14. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa.
Wuillemin WA; Eldering E; Citarella F; de Ruig CP; ten Cate H; Hack CE
J Biol Chem; 1996 May; 271(22):12913-8. PubMed ID: 8662679
[TBL] [Abstract][Full Text] [Related]
15. Predictive value for increased activated factor XI activity in acute venous thromboembolism.
Nagy M; Robles AP; Visser M; Koeck T; Ten Cate V; Ten Cate-Hoek AJ; Schwers S; Heitmeier S; Ten Cate H; Wild PS; Spronk HMH
J Thromb Haemost; 2023 Jun; 21(6):1610-1622. PubMed ID: 37003466
[TBL] [Abstract][Full Text] [Related]
16. Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX.
Sun MF; Zhao M; Gailani D
J Biol Chem; 1999 Dec; 274(51):36373-8. PubMed ID: 10593931
[TBL] [Abstract][Full Text] [Related]
17. The mechanism underlying activation of factor IX by factor XIa.
Gailani D; Geng Y; Verhamme I; Sun MF; Bajaj SP; Messer A; Emsley J
Thromb Res; 2014 May; 133 Suppl 1(0 1):S48-51. PubMed ID: 24759143
[TBL] [Abstract][Full Text] [Related]
18. Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential.
Gailani D; Ho D; Sun MF; Cheng Q; Walsh PN
Blood; 2001 May; 97(10):3117-22. PubMed ID: 11342438
[TBL] [Abstract][Full Text] [Related]
19. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation.
Baird TR; Walsh PN
J Biol Chem; 2002 Oct; 277(41):38462-7. PubMed ID: 12167623
[TBL] [Abstract][Full Text] [Related]
20. SERPIN regulation of factor XIa. The novel observation that protease nexin 1 in the presence of heparin is a more potent inhibitor of factor XIa than C1 inhibitor.
Knauer DJ; Majumdar D; Fong PC; Knauer MF
J Biol Chem; 2000 Dec; 275(48):37340-6. PubMed ID: 10973954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
